Prostate Cancer Clinical Trial
Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer
Summary
This phase I trial is studying the side effects and best dose of photodynamic therapy with lutetium texaphyrin in treating patients with locally recurrent prostate cancer. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for locally recurrent prostate cancer. Photosensitizing drugs, such as lutetium texaphyrin, are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells
Full Description
PRIMARY OBJECTIVES:
I. Determine the dose limiting toxicities and maximum tolerated dose of photodynamic therapy (PDT) using 730 nm light and lutetium texaphyrin in patients with locally recurrent prostate adenocarcinoma who have failed previous definitive radiotherapy.
SECONDARY OBJECTIVES:
I. Measure lutetium texaphyrin levels in needle biopsies of the prostate before and after PDT using an HPLC and tissue fluorescence assay and calculate the percent change in lutetium texaphyrin after treatment.
II. Measure lutetium texaphyrin fluorescence in situ in the prostate before and after PDT using optical methods and correlate these results with the direct tissue measurements made in the biopsies of these patients.
III. Determine clinical outcome including clinical response, progression free survival, time to complete response, time to biochemical relapse, time to local progression, time to distant failure, overall survival, and disease specific survival in these patients treated with this regimen.
OUTLINE: This is a dose-escalation study of lutetium texaphyrin and light fluence.
Patients receive lutetium texaphyrin IV over 10-15 minutes 3-24 hours before photodynamic therapy (PDT). Optical fibers attached to a laser are inserted through a catheter into the prostate. The laser delivers 730 nm light to the prostate until the specified fluence is delivered. Patients undergo biopsy of the prostate and bladder before and after PDT. Cohorts of 3-6 patients receive escalating doses of lutetium texaphyrin and light fluence until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
Patients are followed at 2 weeks, 1 month, 2 months, 3 months, then every 3 months until 2 years, then every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A minimum of 24 patients will be accrued for this study within 3 years.
Eligibility Criteria
Inclusion Criteria:
Histologically proven locally recurrent prostate adenocarcinoma previously treated with definitive radiotherapy
No T3 or T4 primary tumors
No evidence of regional or distant metastases by MRI or bone scan
No pathologic demonstration of malignancy in pelvic or abdominal lymph nodes
Prostate gland volume no greater than 50 mL by MRI or ultrasound
PSA no greater than 20 ng/mL
Performance status - ECOG 0-2
WBC at least 2,000/mm^3
Platelet count at least 100,000/mm^3
No severe liver disease (e.g., cirrhosis or grade III-IV elevations in liver function studies)
Bilirubin no greater than 1.5 mg/dL
Creatinine normal
Creatinine clearance at least 60 mL/min
Medical suitability for implantation
Fertile patients must use effective contraception during and for 6 months after study participation
No history of grade III or IV genitourinary or gastrointestinal toxicity
No known G6PD deficiency
No porphyria
At least 4 weeks since prior gene therapy
At least 4 weeks since prior immunotherapy
At least 4 weeks since prior combination chemotherapy
No concurrent chemotherapy
At least 4 weeks since prior hormonal therapy
No concurrent hormonal therapy
No prior cryosurgery for prostate cancer
No other concurrent medication for prostate cancer
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19104, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.